BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 26849221)

  • 1. Identifying Patient-Specific Epstein-Barr Nuclear Antigen-1 Genetic Variation and Potential Autoreactive Targets Relevant to Multiple Sclerosis Pathogenesis.
    Tschochner M; Leary S; Cooper D; Strautins K; Chopra A; Clark H; Choo L; Dunn D; James I; Carroll WM; Kermode AG; Nolan D
    PLoS One; 2016; 11(2):e0147567. PubMed ID: 26849221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15.
    Zdimerova H; Murer A; Engelmann C; Raykova A; Deng Y; Gujer C; Rühl J; McHugh D; Caduff N; Naghavian R; Pezzino G; Capaul R; Zbinden A; Ferlazzo G; Lünemann JD; Martin R; Chatterjee B; Münz C
    Eur J Immunol; 2021 Jan; 51(1):64-75. PubMed ID: 32949466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes.
    Rajnavölgyi E; Nagy N; Thuresson B; Dosztányi Z; Simon A; Simon I; Karr RW; Ernberg I; Klein E; Falk KI
    Int Immunol; 2000 Mar; 12(3):281-93. PubMed ID: 10700463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model.
    Jog NR; McClain MT; Heinlen LD; Gross T; Towner R; Guthridge JM; Axtell RC; Pardo G; Harley JB; James JA
    J Autoimmun; 2020 Jan; 106():102332. PubMed ID: 31515129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus infection and variants of Epstein-Barr nuclear antigen-1 in synovial tissues of rheumatoid arthritis.
    Masuoka S; Kusunoki N; Takamatsu R; Takahashi H; Tsuchiya K; Kawai S; Nanki T
    PLoS One; 2018; 13(12):e0208957. PubMed ID: 30533036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating risk factors: HLA-DRB1*1501 and Epstein-Barr virus in multiple sclerosis.
    De Jager PL; Simon KC; Munger KL; Rioux JD; Hafler DA; Ascherio A
    Neurology; 2008 Mar; 70(13 Pt 2):1113-8. PubMed ID: 18272866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.
    Meier UC; Cipian RC; Karimi A; Ramasamy R; Middeldorp JM
    Front Immunol; 2021; 12():757302. PubMed ID: 34790199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.
    Tengvall K; Huang J; Hellström C; Kammer P; Biström M; Ayoglu B; Lima Bomfim I; Stridh P; Butt J; Brenner N; Michel A; Lundberg K; Padyukov L; Lundberg IE; Svenungsson E; Ernberg I; Olafsson S; Dilthey AT; Hillert J; Alfredsson L; Sundström P; Nilsson P; Waterboer T; Olsson T; Kockum I
    Proc Natl Acad Sci U S A; 2019 Aug; 116(34):16955-16960. PubMed ID: 31375628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA DR2b-binding peptides from human endogenous retrovirus envelope, Epstein-Barr virus and brain proteins in the context of molecular mimicry in multiple sclerosis.
    Ramasamy R; Mohammed F; Meier UC
    Immunol Lett; 2020 Jan; 217():15-24. PubMed ID: 31689443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response.
    Bell MJ; Brennan R; Miles JJ; Moss DJ; Burrows JM; Burrows SR
    J Infect Dis; 2008 Jun; 197(11):1594-7. PubMed ID: 18419576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
    Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
    Strautins K; Tschochner M; James I; Choo L; Dunn DS; Pedrini M; Kermode A; Carroll W; Nolan D
    Mult Scler; 2014 Mar; 20(3):286-94. PubMed ID: 23886832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2.
    Lünemann JD; Jelcić I; Roberts S; Lutterotti A; Tackenberg B; Martin R; Münz C
    J Exp Med; 2008 Aug; 205(8):1763-73. PubMed ID: 18663124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
    Wang Z; Kennedy PG; Dupree C; Wang M; Lee C; Pointon T; Langford TD; Graner MW; Yu X
    J Neuroimmune Pharmacol; 2021 Sep; 16(3):567-580. PubMed ID: 32808238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
    Fogg MH; Wirth LJ; Posner M; Wang F
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
    Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
    Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.
    Ruprecht K; Wunderlich B; Gieß R; Meyer P; Loebel M; Lenz K; Hofmann J; Rosche B; Wengert O; Paul F; Reimer U; Scheibenbogen C
    J Neuroimmunol; 2014 Jul; 272(1-2):56-61. PubMed ID: 24798244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
    Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
    PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus candidate genes and multiple sclerosis.
    Claire Simon K; Schmidt H; Loud S; Ascherio A
    Mult Scler Relat Disord; 2015 Jan; 4(1):60-4. PubMed ID: 25787055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic and sequence variation in the C-terminal unique domain of the Epstein-Barr virus nuclear antigen EBNA-1.
    Wrightham MN; Stewart JP; Janjua NJ; Pepper SD; Sample C; Rooney CM; Arrand JR
    Virology; 1995 Apr; 208(2):521-30. PubMed ID: 7538250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.